Core Viewpoint - Jincheng Pharmaceutical is a leading enterprise in the domestic cephalosporin sector, with a comprehensive industry chain advantage, focusing on the research, production, and sales of pharmaceutical intermediates, active pharmaceutical ingredients, and finished formulations [1] Group 1: Business Performance - For Q3 2025, Jincheng Pharmaceutical reported revenue of 1.932 billion yuan, ranking 34th among 110 companies in the industry, while the industry leader, East China Pharmaceutical, achieved revenue of 32.664 billion yuan [2] - The net profit for the same period was 33.5981 million yuan, placing the company 67th in the industry, with the top performer, Hengrui Medicine, reporting a net profit of 5.76 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, Jincheng Pharmaceutical's debt-to-asset ratio was 27.69%, lower than the previous year's 32.87% and below the industry average of 35.26%, indicating strong solvency [3] - The gross profit margin for Q3 2025 was 36.23%, down from 40.13% year-on-year and below the industry average of 57.17% [3] Group 3: Executive Compensation - The chairman, Zhao Yeqing, received a salary of 2.035 million yuan in 2024, an increase of 36,000 yuan from 2023 [4] - The president, Li Jiaquan, earned 1.833 million yuan in 2024, up by 34,000 yuan from the previous year [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 8.49% to 25,800, while the average number of circulating A-shares held per shareholder increased by 9.27% to 14,400 [5] - Notable changes among the top ten circulating shareholders include the new entry of Fu Guo Precision Medical Flexible Allocation Mixed A, holding 4.961 million shares, and a reduction in holdings by Hong Kong Central Clearing Limited [5]

Company Overview - Dezheng Health was established on January 1, 1981, and listed on the Shenzhen Stock Exchange on May 19, 1998. The company is headquartered in Urumqi, Xinjiang, with its office located in Beijing. It is a leading enterprise in the research and manufacturing of cardiovascular drugs in China, with its core product being Alet (Atorvastatin Calcium Tablets), which has both brand and technological advantages [1] Financial Performance - In Q3 2025, Dezheng Health achieved a revenue of 278 million yuan, ranking 93rd among 110 companies in the industry. The top company, Huadong Medicine, reported a revenue of 32.664 billion yuan, while the second, Fosun Pharma, reported 29.393 billion yuan. The industry average revenue was 280 million yuan, with a median of 83.8 million yuan [2] - The net profit for the same period was -88.5372 million yuan, ranking 91st in the industry. The leading company, Heng Rui Medicine, reported a net profit of 5.76 billion yuan, and Fosun Pharma reported 3.056 billion yuan. The industry average net profit was 299 million yuan, with a median of 78.2908 million yuan [2] Financial Ratios - As of Q3 2025, Dezheng Health's debt-to-asset ratio was 5.18%, up from 2.63% in the same period last year, significantly lower than the industry average of 35.26%, indicating strong solvency [3] - The gross profit margin for Q3 2025 was 55.57%, down from 61.46% in the previous year, slightly below the industry average of 57.17% [3] Leadership - The controlling shareholder of Dezheng Health is Xinjiang Kaidi Investment Co., Ltd., with the actual controller being the State-owned Assets Supervision and Administration Commission of the Xinjiang Uygur Autonomous Region. The chairman, Wei Zheming, born in November 1982, holds a master's degree in business administration and has extensive management and investment experience. He has held significant positions in various companies, including Tebian Electric Apparatus and Xinjiang Lianchuang Yongjin. The general manager, Liu Wei, born in January 1970, is a licensed pharmacist with a salary of 3.98 million yuan in 2024, unchanged from 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders of Dezheng Health was 57,600, a decrease of 1.13% from the previous period. The average number of circulating A-shares held per household was 36,400, down by 2.03%. Additionally, as of the same date, Hong Kong Central Clearing Limited exited the list of the top ten circulating shareholders [5]

Core Viewpoint - Yifan Pharmaceutical is a global pharmaceutical company with significant technological advantages, particularly in its core product, Yili Shou, which is the first G-CSF-Fc fusion protein product approved for sale in China [1] Group 1: Business Performance - In Q3 2025, Yifan Pharmaceutical reported revenue of 3.923 billion yuan, ranking 19th among 110 companies in the industry [2] - The company's net profit for the same period was 360 million yuan, placing it 26th in the industry [2] - The company's revenue growth in H1 2025 was 0.11% year-on-year, while net profit increased by 19.91% [6][7] Group 2: Financial Ratios - As of Q3 2025, Yifan Pharmaceutical's debt-to-asset ratio was 33.55%, lower than the industry average of 35.26% [3] - The gross profit margin for Q3 2025 was 47.82%, which is below the industry average of 57.17% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 0.46% to 46,600 [5] - The average number of circulating A-shares held per shareholder increased by 0.46% to 18,000 [5] Group 4: Executive Compensation - The chairman and president, Cheng Xianfeng, received a salary of 624,000 yuan in 2024, unchanged from 2023 [4] Group 5: Market Outlook - Yifan Pharmaceutical's innovative drugs, Yili Shou and Yini Kang, saw a combined sales revenue increase of 169.57% compared to the previous year [6][7] - The company is expected to achieve annual sales of Yili Shou reaching 1 billion yuan [6] - Forecasts for the company's revenue in 2025, 2026, and 2027 are 5.833 billion, 6.838 billion, and 7.945 billion yuan, respectively [6][7]

Core Viewpoint - Fulejia, a well-known company in the professional skin care sector, was established on November 28, 2017, and went public on August 1, 2023, in Shenzhen. The company has a strong market position due to its high-quality products and robust R&D capabilities [1]. Group 1: Business Performance - In Q3 2025, Fulejia reported revenue of 1.297 billion yuan, ranking 7th among 8 companies in the industry. The top company, Proya, had revenue of 7.098 billion yuan, while the industry average was 3.238 billion yuan [2]. - The main business composition showed that cosmetic revenue was 625 million yuan, accounting for 72.39%, while medical device revenue was 238 million yuan, making up 27.61% [2]. - The net profit for the same period was 325 million yuan, ranking 3rd in the industry, with Proya leading at 1.055 billion yuan and the industry average at 329 million yuan [2]. Group 2: Financial Health - Fulejia's debt-to-asset ratio was 3.60% in Q3 2025, slightly down from 3.62% the previous year, significantly lower than the industry average of 25.15%, indicating strong solvency and low financial risk [3]. - The gross profit margin was 81.11%, slightly down from 81.65% year-on-year, but still above the industry average of 66.60%, reflecting strong profitability [3]. Group 3: Management and Shareholder Information - Chairman Zhang Liguan's salary for 2024 was 619,400 yuan, a decrease of 3,000 yuan from 2023. The general manager, Sun Na, had a salary of 1.8298 million yuan, down 37,000 yuan from the previous year [4]. - As of September 30, 2025, the number of A-share shareholders decreased by 1.29% to 14,800, with an average holding of 5,229.49 shares, an increase of 1.22% [5]. Group 4: Market Trends and Future Outlook - According to Changjiang Securities, Fulejia's cosmetic segment showed steady growth in H1 2025, with revenues of 620 million yuan, a year-on-year increase of 29.95%, while medical device revenue saw a decline of 48% [6]. - The online sales channel performed exceptionally well, with online revenue reaching 690 million yuan, a 47% increase year-on-year, while offline sales dropped by 64% [6]. - The company is expected to see earnings per share (EPS) of 1.04, 1.16, and 1.28 yuan for 2025 to 2027, maintaining a "buy" rating [6].

Core Viewpoint - Xintiandi is a leading supplier of chiral pharmaceutical intermediates in China, with a full industry chain advantage and product quality meeting international standards [1] Group 1: Company Overview - Xintiandi was established on September 15, 2005, and was listed on the Shenzhen Stock Exchange on November 16, 2022, with its registered and office location in Henan Province [1] - The company primarily engages in the research, development, production, and sales of chiral pharmaceutical intermediates, operating within the pharmaceutical and biological - chemical pharmaceutical - raw materials sector [1] Group 2: Financial Performance - For Q3 2025, Xintiandi reported revenue of 481 million yuan, ranking 30th among 47 companies in the industry, while the industry leader, Prolo Pharmaceutical, achieved 7.764 billion yuan [2] - The main business composition includes L-phenylalanine series products at 300 million yuan, accounting for 83.74%, and p-toluenesulfonic acid at 52.862 million yuan, accounting for 14.78% [2] - The net profit for the same period was 91.27 million yuan, ranking 20th in the industry, with the industry leader, Zhejiang Pharmaceutical, reporting 867 million yuan [2] Group 3: Financial Ratios - As of Q3 2025, Xintiandi's debt-to-asset ratio was 12.74%, lower than the previous year's 13.12% and significantly below the industry average of 27.75%, indicating strong solvency [3] - The gross profit margin for the period was 35.86%, which, although lower than the previous year's 41.01%, remains above the industry average of 35.38% [3] Group 4: Executive Compensation - The chairman, Xie Jianzhong, received a salary of 585,400 yuan in 2024, an increase of 18,100 yuan from 2023 [4] - The general manager, Zhang Luwei, earned 488,000 yuan in 2024, up by 5,600 yuan from the previous year [4] Group 5: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 0.66% to 18,500, while the average number of circulating A-shares held per household increased by 0.66% to 5,448.09 [5]

Core Viewpoint - 博瑞医药 is a leading high-end generic and innovative drug developer in China, with a strong industry position and full supply chain advantages [1] Financial Performance - In Q3 2025, 博瑞医药 achieved revenue of 874 million yuan, ranking 20th among 47 companies in the industry, while the industry leader, 普洛药业, reported revenue of 7.764 billion yuan [2] - The company's net profit for the same period was 31.39 million yuan, placing it 29th in the industry, with the top performer, 浙江医药, reporting a net profit of 867 million yuan [2] Profitability and Debt - As of Q3 2025, 博瑞医药's debt-to-asset ratio was 52.77%, higher than the industry average of 27.75%, indicating significant debt pressure [3] - The gross profit margin was 51.40%, which, despite a decrease from 58.00% year-on-year, remains above the industry average of 35.38% [3] Management and Shareholder Structure - The chairman, 袁建栋, received a salary of 1.9114 million yuan in 2024, a slight decrease from the previous year [4] - As of June 30, 2025, the number of A-share shareholders decreased by 10.11%, while the average number of shares held per shareholder increased by 11.32% [5] Innovation Pipeline - 博瑞医药's BGM0504 oral tablet has received Phase I clinical trial approval in the U.S., showcasing significant advantages in bioavailability and safety [5] - The company has a rich pipeline with multiple products progressing towards clinical stages, enhancing its competitiveness in international markets [5][6] Market Outlook - Despite a temporary decline in revenue and net profit due to reduced demand for antiviral products, the company is expected to improve its performance with ongoing innovation and clinical advancements [6]

Core Viewpoint - Boen Group, a well-known company in the domestic feed industry, focuses on the research, production, and sales of feed, showcasing strong technical research capabilities and product quality advantages [1] Group 1: Business Performance - In Q3 2025, Boen Group's revenue was 976 million yuan, ranking 8th among 10 companies in the industry, with the industry leader, He Feng Co., achieving 28.073 billion yuan [2] - The main business revenue from feed sales was 612 million yuan, accounting for 99.76% of total revenue, while other revenues were 1.4646 million yuan, making up 0.24% [2] - The net profit for the same period was -9.9611 million yuan, ranking 6th in the industry, with the industry leader, Tian Kang Biological, reporting a net profit of 505 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, Boen Group's debt-to-asset ratio was 29.93%, up from 19.95% year-on-year, which is lower than the industry average of 54.11%, indicating strong debt repayment capability [3] - The gross profit margin for Q3 2025 was 12.47%, down from 14.04% year-on-year, but still above the industry average of 9.94%, reflecting good profitability [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 1.28% to 9,732, while the average number of circulating A-shares held per shareholder increased by 1.29% to 5,721.33 [5] - Among the top ten circulating shareholders, Noan Multi-Strategy Mixed A ranked fourth with 1.1246 million shares, an increase of 288,000 shares from the previous period [5]

Core Viewpoint - Weigao Bio is a significant player in the domestic blood products sector, focusing on the production and research of blood products, with a strong technical barrier and a diverse product line [1] Group 1: Business Performance - In Q3 2025, Weigao Bio reported revenue of 791 million, ranking 5th in the industry, with the top competitor, Shanghai Raas, generating 6.091 billion [2] - The company's net profit for the same period was 158 million, also ranking 5th, while the industry leader reported a net profit of 1.47 billion [2] Group 2: Financial Ratios - As of Q3 2025, Weigao Bio's debt-to-asset ratio was 30.56%, higher than the industry average of 28.01% [3] - The gross profit margin for Q3 2025 was 42.47%, which is below the industry average of 44.76% [3] Group 3: Executive Compensation - The chairman, Zhang Zhan, received a salary of 1.2442 million in 2024, an increase of 21,600 from 2023 [4] - The general manager, Guo Caiping, also received a salary of 1.2442 million in 2024, up by 33,800 from the previous year [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 0.70% to 12,500, while the average number of shares held per shareholder increased by 0.70% to 18,100 [5] - Hong Kong Central Clearing Limited became a new major shareholder, holding 679,400 shares [5] Group 5: Future Outlook - Huazheng Securities predicts that Weigao Bio will achieve revenue and profit growth in 2024, with a notable increase in non-recurring net profit [5] - The company is expected to see revenue of 1.347 billion, 1.497 billion, and 1.653 billion from 2025 to 2027, with net profits of 299 million, 345 million, and 396 million respectively [5] - Zhongyou Securities anticipates steady growth in 2024, with a recovery in blood product business expected [6]

Core Insights - Qingsong Co., Ltd. is a leading ODM enterprise in the cosmetics industry, established in 2001 and listed in 2010, with a strong R&D capability and diverse product lines [1] Financial Performance - In Q3 2025, Qingsong's revenue reached 1.553 billion yuan, ranking first among seven companies in the industry, surpassing the second-ranked Qingdao Kingway's 1.246 billion yuan and the industry average of 842 million yuan [2] - The net profit for the same period was 107 million yuan, also the highest in the industry, exceeding the second-ranked Kesi's 73.628 million yuan and the industry average of 37.206 million yuan [2] Business Segmentation - The main business segments include facial masks (450 million yuan, 48.07%), skincare products (323 million yuan, 34.47%), wet wipes (125 million yuan, 13.36%), and other products (29.577 million yuan, 3.16%) [2] Financial Ratios - As of Q3 2025, the asset-liability ratio was 36.14%, a decrease from 42.74% year-on-year, slightly above the industry average of 36.05% [3] - The gross profit margin was 19.20%, an increase from 16.56% year-on-year, but below the industry average of 21.95% [3] Executive Compensation - Chairman and CEO Fan Zhanhua's compensation for 2024 was 1.2222 million yuan, an increase of 653,600 yuan from 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 15.93% to 25,300, while the average number of circulating A-shares held per shareholder increased by 18.95% to 20,100 [5] Market Outlook - Qingsong aims to become a world-class cosmetics manufacturing service provider, focusing on enhancing customer service and R&D innovation [5] - Revenue forecasts for 2025 have been adjusted to 2.089 billion yuan, with an increase in gross margin to 17.4% and a decrease in profit forecast to 104 million yuan [5] - Qingsong's net profit projections for 2025-2027 are 104 million, 119 million, and 139 million yuan, with corresponding PE ratios of 27, 23, and 20 [5] Competitive Position - Qingsong is recognized as one of the largest domestic ODM enterprises in cosmetics, with six competitive advantages and multiple business departments to enhance service quality [6]